[PDF] springer.com

Cytokine release syndrome: inhibition of pro-inflammatory cytokines as a solution for reducing COVID-19 mortality

N Moradian, M Gouravani, MA Salehi, A Heidari… - European cytokine …, 2020 - Springer
Abstract Coronavirus disease (COVID-19) reached pandemic proportions at the beginning
of 2020 and continues to be a worldwide concern. End organ damage and acute respiratory …
被引用次数：50 相关文章 所有 11 个版本
[HTML] nih.gov

Cytokine release syndrome in COVID-19: a major mechanism of morbidity and mortality

Y Que, C Hu, K Wan, P Hu, R Wang, J Luo… - International reviews …, 2022 - Taylor & Francis
Abstract The coronavirus disease 2019 (COVID-19) triggered by severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) erupted in Hubei Province of China in December …
被引用次数：140 相关文章 所有 7 个版本
[PDF] spandidos-publications.com

Interleukin‑6 signaling blockade treatment for cytokine release syndrome in COVID‑19

JJ Chen, LN Zhang, H Hou… - Experimental and …, 2021 - spandidos-publications.com
A severe immune response in patients with coronavirus disease 2019 (COVID‑19) can
cause a potentially lethal unconstrained inflammatory cytokine storm, known as cytokine …
被引用次数：26 相关文章 所有 12 个版本
[HTML] nih.gov

The deregulated immune reaction and cytokines release storm (CRS) in COVID-19 disease

R Pasrija, M Naime - International Immunopharmacology, 2021 - Elsevier
COVID-19 caused by the SARS-CoV-2 virus, accompanies an unprecedented spike in
cytokines levels termed cytokines release syndrome (CRS), in critically ill patients. Clinicians …
被引用次数：104 相关文章 所有 6 个版本
[HTML] nih.gov

[HTML][HTML] Role of IL-6 inhibitor in treatment of COVID-19-related cytokine release syndrome

P Du, J Geng, F Wang, X Chen, Z Huang… - International journal of …, 2021 - ncbi.nlm.nih.gov
Cytokine release syndrome (CRS) may be the key factor in the pathology of severe
coronavirus disease 2019 (COVID-19). As a major driver in triggering CRS in patients with …
被引用次数：66 相关文章 所有 10 个版本
[HTML] nih.gov

Cytokine release syndrome in severe COVID-19: interleukin-6 receptor antagonist tocilizumab may be the key to reduce mortality

C Zhang, Z Wu, JW Li, H Zhao, GQ Wang - International journal of …, 2020 - Elsevier
Since December 2019, a viral pneumonia, named coronavirus disease 2019 (COVID-19),
from Wuhan, China, has swept the world. Although the case fatality rate is not high, the …
被引用次数：2117 相关文章 所有 15 个版本

Therapeutics for the management of cytokine release syndrome in COVID-19

S Ghosh, S Durgvanshi, SS Han… - Current topics in …, 2023 - ingentaconnect.com
Coronavirus disease (COVID-19) is the greatest pandemic of this era and has affected more
than 10 million people across 213 nations. However, the etiology, management, and …
被引用次数：9 相关文章 所有 4 个版本
[PDF] tandfonline.com

Overview on the use of IL-6 agents in the treatment of patients with cytokine release syndrome (CRS) and pneumonitis related to COVID-19 disease

Z Zhou, CC Price - Expert opinion on investigational drugs, 2020 - Taylor & Francis
Introduction A novel coronavirus pneumonia (COVID-19) has caused significant life loss and
healthcare burden globally. COVID-19 is known to cause a cytokine release syndrome …
被引用次数：23 相关文章 所有 6 个版本
[PDF] nature.com

Clinical characterization and risk factors associated with cytokine release syndrome induced by COVID-19 and chimeric antigen receptor T-cell therapy

R Hong, H Zhao, Y Wang, Y Chen, H Cai… - Bone marrow …, 2021 - nature.com
An excessive immune response during coronavirus disease (COVID-19) can induce
cytokine release syndrome (CRS), which is associated with life-threatening complications …
被引用次数：35 相关文章 所有 11 个版本
[PDF] 2pressrelease.co.in

Cytokine storm in COVID-19: Potential therapeutics for immunomodulation

MM Rana - Journal of Research in Clinical Medicine, 2020 - library.2pressrelease.co.in
The outbreak of new coronavirus disease-20119 or COVID-19 infection has become a
global health emergency at the beginning of this year. Currently, no specific vaccines and …
被引用次数：17 相关文章 所有 7 个版本